A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Journal of cancer research and clinical oncology, 147.2021, 8, S. 2373-2383
- Ereignis
-
Veröffentlichung
- (wo)
-
Frankfurt am Main
- (wer)
-
Universitätsbibliothek Johann Christian Senckenberg
- (wann)
-
2021
- Urheber
- DOI
-
10.1007/s00432-021-03511-y
- URN
-
urn:nbn:de:hebis:30:3-637423
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Steidl, Eike
- Filipski, Katharina Johanna
- Zeiner, Pia Susan
- Wagner, Marlies
- Fokas, Emmanouil
- Forster, Marie-Thérèse
- Ronellenfitsch, Michael Wilfried
- Divé, Iris
- Steinbach, Joachim Peter
- Harter, Patrick Nikolaus
- Bähr, Roy Oliver
- Universitätsbibliothek Johann Christian Senckenberg
Entstanden
- 2021
Ähnliche Objekte (12)
A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy
Glioma and temozolomide induced alterations in gut microbiome
Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2
Perfusion and permeability MRI in glioma grading
Investigating New Drug Options for Temozolomide Resistant IDH1 Mutant Glioma
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
CircKIF4A promotes glioma growth and temozolomide resistance by accelerating glycolysis
Metalloproteases involved in the Temozolomide (TMZ) resistance of U87-MG glioma cells
Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma
Metalloproteases involved in the Temozolomide (TMZ) resistance of U87-MG glioma cells
Resveratrol abrogates the Temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the Temozolomide-induced senescence in glioma cells
Feasibility of generalised diffusion kurtosis imaging approach for brain glioma grading
A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy
Glioma and temozolomide induced alterations in gut microbiome
Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2
Perfusion and permeability MRI in glioma grading
Investigating New Drug Options for Temozolomide Resistant IDH1 Mutant Glioma
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
CircKIF4A promotes glioma growth and temozolomide resistance by accelerating glycolysis
Metalloproteases involved in the Temozolomide (TMZ) resistance of U87-MG glioma cells
Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma
Metalloproteases involved in the Temozolomide (TMZ) resistance of U87-MG glioma cells
Resveratrol abrogates the Temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the Temozolomide-induced senescence in glioma cells
Feasibility of generalised diffusion kurtosis imaging approach for brain glioma grading
A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy
Glioma and temozolomide induced alterations in gut microbiome
Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2
Perfusion and permeability MRI in glioma grading
Investigating New Drug Options for Temozolomide Resistant IDH1 Mutant Glioma
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
CircKIF4A promotes glioma growth and temozolomide resistance by accelerating glycolysis
Metalloproteases involved in the Temozolomide (TMZ) resistance of U87-MG glioma cells
Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma
Metalloproteases involved in the Temozolomide (TMZ) resistance of U87-MG glioma cells
Resveratrol abrogates the Temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the Temozolomide-induced senescence in glioma cells